KYMR Insider Trading

Insider Ownership Percentage: 15.82%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $20,632,414.35

Kymera Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$455ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Kymera Therapeutics Share Price & Price History

Current Price: $29.62
Price Change: Price Decrease of -0.58 (-1.92%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for KYMR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$29.62Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Kymera Therapeutics (NASDAQ:KYMR)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KYMR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$129Mbought$59MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More on Kymera Therapeutics

Today's Range

Now: $29.62
Low: $29.34
High: $30.42

50 Day Range

MA: $35.86
Low: $29.62
High: $44.36

52 Week Range

Now: $29.62
Low: $29.07
High: $53.27

Volume

357,093 shs

Average Volume

522,181 shs

Market Capitalization

$1.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Who are the company insiders with the largest holdings of Kymera Therapeutics?

Kymera Therapeutics' top insider shareholders include:
  1. Venture Fund X LP Atlas (Major Shareholder)
  2. Bvf Partners L P/Il (Director)
  3. Bruce Booth (Director)
  4. Bruce N Jacobs (CFO)
  5. Jared Gollob (Insider)
  6. Ellen Chiniara (Insider)
  7. Jeremy G Chadwick (COO)
  8. Jeffrey W Albers (Director)
  9. Joanna Horobin (Director)
  10. Pamela Esposito (Director)
Learn More about top insider investors at Kymera Therapeutics.

Who are the major institutional investors of Kymera Therapeutics?

Kymera Therapeutics' top institutional shareholders include:
  1. Price T Rowe Associates Inc. MD — 10.61%
  2. Wellington Management Group LLP — 8.17%
  3. Avoro Capital Advisors LLC — 7.95%
  4. Vanguard Group Inc. — 7.55%
  5. FMR LLC — 7.46%
  6. Driehaus Capital Management LLC — 2.15%
Learn More about top institutional investors of Kymera Therapeutics stock.

Which major investors are selling Kymera Therapeutics stock?

During the previous quarter, KYMR stock was sold by these institutional investors:
  1. Redmile Group LLC
  2. FMR LLC
  3. Frontier Capital Management Co. LLC
  4. Invesco Ltd.
  5. Marshall Wace LLP
  6. D. E. Shaw & Co. Inc.
  7. JPMorgan Chase & Co.
  8. Two Sigma Investments LP
Within the previous year, company insiders that have sold Kymera Therapeutics company stock include:
  1. Venture Fund X LP Atlas (Major Shareholder)
  2. Bvf Partners L P/Il (Director)
  3. Bruce Booth (Director)
  4. Bruce N Jacobs (CFO)
  5. Jared Gollob (Insider)
  6. Ellen Chiniara (Insider)
  7. Jeremy G Chadwick (COO)
  8. Jeffrey W Albers (Director)
Learn More investors selling Kymera Therapeutics stock.

Which major investors are buying Kymera Therapeutics stock?

In the previous quarter, KYMR stock was purchased by institutional investors including:
  1. Wellington Management Group LLP
  2. Avoro Capital Advisors LLC
  3. Deerfield Management Company L.P. Series C
  4. Boxer Capital Management LLC
  5. Janus Henderson Group PLC
  6. Price T Rowe Associates Inc. MD
  7. Foresite Capital Management VI LLC
  8. Vanguard Group Inc.